Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 18:57 ET | Source: Biomerica, Inc.

Biomerica Reports Third Quarter Fiscal 2026 Financial Results

IRVINE, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (“Biomerica” or the “Company”) a global provider of advanced medical diagnostic and therapeutic products today...
April 13, 2026 16:46 ET | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody...
April 13, 2026 16:38 ET | Source: ImmuCell Corporation

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to...
April 13, 2026 16:05 ET | Source: TheRas, Inc. (d/b/a BBOT)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 13, 2026 13:55 ET | Source: Seer, Inc.

Seer Confirms Receipt of Unsolicited Proposal and Director Candidate Nominations from Radoff-JEC Group

REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed...
April 13, 2026 09:35 ET | Source: Genmab A/S

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

Media ReleaseCOPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S®) and bevacizumab was tolerable, with no new safety signals in...
April 13, 2026 09:20 ET | Source: BiomX

BiomX Accelerates Defense Technology Buildout with DFSL Acquisition

NETANYA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE: PHGE) (“BiomX" or the “Company") today announced that it has accelerated the exercise of its previously disclosed exclusive...
April 13, 2026 09:15 ET | Source: PolyPid Ltd.

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

PETACH TIKVA, Israel, April 13, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by...
April 13, 2026 09:00 ET | Source: Senti Biosciences, Inc.

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...
April 13, 2026 09:00 ET | Source: Neomorph, Inc.

Neomorph Announces Closing of $100 Million Series B Financing

SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a...